Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.8 SAR | -0.74% | -1.18% | -2.34% |
May. 08 | Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises | MT |
Mar. 18 | Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.34% | 4.67B | D- | ||
-38.61% | 13.83B | B- | ||
-31.33% | 10.96B | B | ||
+13.51% | 6.34B | C | ||
-8.33% | 6.08B | C+ | ||
-30.66% | 6.05B | B | ||
+72.00% | 4.98B | C | ||
-4.84% | 4B | B | ||
-16.14% | 3.28B | C- | ||
-12.02% | 2.86B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4164 Stock
- Ratings Nahdi Medical Company